Changeflow GovPing Pharma & Drug Safety GlaxoSmithKline Meningococcus Vaccine Patent Ap...
Routine Notice Added Final

GlaxoSmithKline Meningococcus Vaccine Patent Application US20260097107A1

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO published patent application US20260097107A1 for GlaxoSmithKline Biologicals SA covering meningococcal vaccines containing multiple alleles or variants of the fHbp protein to broaden coverage. The application was filed on October 29, 2025, and names inventors Alessia BIOLCHI, Brunella BRUNELLI, Marzia Monica GIULIANI, and Vega MASIGNANI.

What changed

The USPTO published a patent application (US20260097107A1) filed by GlaxoSmithKline Biologicals SA for meningococcal vaccines incorporating multiple alleles or variants of Factor H binding protein (fHbp) to provide broader coverage against diverse meningococcal strains and/or reduce OMV component quantity per dose.

Competitors developing meningococcal vaccines should monitor this patent's claims for freedom-to-operate considerations. Other pharmaceutical companies may seek licensing arrangements if the technology proves commercially valuable. This patent publication does not create immediate compliance obligations but establishes intellectual property rights that may affect future vaccine development strategies.

What to do next

  1. Monitor patent claims for freedom-to-operate analysis
  2. Review patent scope for competitive product development implications
  3. Contact GSK licensing department if seeking patent access

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MENINGOCOCCUS VACCINES

Application US20260097107A1 Kind: A1 Apr 09, 2026

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA

Inventors

Alessia BIOLCHI, Brunella BRUNELLI, Marzia Monica GIULIANI, Vega MASIGNANI

Abstract

Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.

CPC Classifications

A61K 39/095 A61K 39/00 A61K 39/116 C07K 14/22 A61K 2039/70 C07K 2319/00

Filing Date

2025-10-29

Application No.

19372898

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260097107A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Vaccine development Biopharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!